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Abstract 
In the past recent years, there has been a substantial progress in the development of 
precise therapies against cancer. However, inference of the likelihood of cancer 
progression and/or therapeutic response based on data of a given cancer driver and/or 
therapeutic target is frequently incomplete. Too often cancer patients show insufficient 
benefit from an indicated therapy and this is in part likely due to incomplete knowledge 
of the molecular modifiers of current therapeutic approaches. Here, we have developed 
and applied an analytical framework to systematically identify the modulators of cancer 
drivers compiled through 15 human cancer types. 
More than 30,000 gene pairs have been identified, and the predictions are robust when 
effects are assessed using protein expression or somatic mutation data. The modulators 
are classified in different biological processes and signaling pathways according to the 
type of gene expression association with the corresponding drivers and to the effect on 
risk (increasing or decreasing) of relapse. While some modulators represent synthetic 
lethal interactions with their corresponding drivers, integration of drug and small 
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compounds information reveals approximately 1,900 instances where cancer relapse 
could be modified. Experimental validations are ongoing. A data web portal will be open 
to the community to facilitate the discovery of new single or combined therapeutic 
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